N01-DK-9-2323/DK/NIDDK NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2002	1
2003	4
2004	3
2005	3
2006	8
2007	6
2008	8
2009	9
2010	13
2011	16
2012	2
2013	1
2014	2
2024	0

1

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. Wai CT, et al. Hepatology. 2003 Aug;38(2):518-26. doi: 10.1053/jhep.2003.50346. Hepatology. 2003. PMID: 12883497 Free article.

2

Navigating the maze of hepatitis B treatments.

Lok AS. Lok AS. Gastroenterology. 2007 Apr;132(4):1586-94. doi: 10.1053/j.gastro.2007.02.040. Epub 2007 Feb 24. Gastroenterology. 2007. PMID: 17408643 Review. No abstract available.

3

Prevention of hepatitis B virus-related hepatocellular carcinoma.

Lok AS. Lok AS. Gastroenterology. 2004 Nov;127(5 Suppl 1):S303-9. doi: 10.1053/j.gastro.2004.09.045. Gastroenterology. 2004. PMID: 15508098 Review.

4

Hepatitis B virus genotypes in the United States: results of a nationwide study.

Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N, Lok AS. Chu CJ, et al. Gastroenterology. 2003 Aug;125(2):444-51. doi: 10.1016/s0016-5085(03)00895-3. Gastroenterology. 2003. PMID: 12891547

5

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok AS, Stoddard AM; HALT-C Trial Group. Fontana RJ, et al. Am J Gastroenterol. 2008 Nov;103(11):2766-75. doi: 10.1111/j.1572-0241.2008.02106.x. Epub 2008 Aug 21. Am J Gastroenterol. 2008. PMID: 18721241 Free PMC article.

6

Prevalence of HBV precore/core promoter variants in the United States.

Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N, Lok AS; U.S. HBV Epidemiology Study Group. Chu CJ, et al. Hepatology. 2003 Sep;38(3):619-28. doi: 10.1053/jhep.2003.50352. Hepatology. 2003. PMID: 12939588 Free article.

7

Treatment of hepatitis B: who, when, and how?

Wong SN, Lok AS. Wong SN, et al. Arch Intern Med. 2006 Jan 9;166(1):9-12. doi: 10.1001/archinte.166.1.9. Arch Intern Med. 2006. PMID: 16401805 No abstract available.

8

Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.

Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group. Lok AS, et al. Hepatology. 2011 Aug;54(2):434-42. doi: 10.1002/hep.24257. Hepatology. 2011. PMID: 21374690 Free PMC article. Clinical Trial.

9

When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?

Degertekin B, Lok AS. Degertekin B, et al. Ann Intern Med. 2007 Jul 3;147(1):62-4. doi: 10.7326/0003-4819-147-1-200707030-00011. Ann Intern Med. 2007. PMID: 17606963 No abstract available.

10

Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States.

Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ, Lee WM, Lok AS; US Acute Liver Failure Study Group. Wai CT, et al. J Viral Hepat. 2005 Mar;12(2):192-8. doi: 10.1111/j.1365-2893.2005.00581.x. J Viral Hepat. 2005. PMID: 15720535 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year